Aldel Financial II Inc. ALDF

Financials SIC 6770 - Blank Checks NAICS Finance and Insurance › Funds, Trusts, and Other Financial Vehicles › Other Investment Pools and Funds › Other Financial Vehicles derived Nasdaq

We are a blank check company incorporated as a Cayman Islands exempted company on July 15, 2024 for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities ("Business Combination").While we are not limited to a particular industry or geographic region for purposes of consummating a Business Combination, we intends to focus on businesses in the financial services industry. We are an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of December 31, 2025, the Company had not yet commenced any operations. All activity through December 31, 2025 relates to the Company's formation and the initial public offering ("IPO"), which is described below. The Company will not generate any operating revenues until after the completion of its Business Combination, at the earliest. The Company has selected December 31 as its fiscal year end.

Last close 10.98 2026-10-14
Market cap $328.0M 2026-03-31 share count
52-week range 10.46 - 10.98

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF34.8x
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024
SG&A $653.5K—
Operating income -$653.5K—
Net income $9.2M—

Balance sheet

Fiscal year FY2025FY2024
Cash and equivalents $541.6K$1.0M
Total current assets $679.7K$1.3M
Total assets $243.7M$234.5M
Accounts payable $28.1K$22.0K
Total liabilities $28.1K$22.0K
Retained earnings $650.8K$1.3M
Total equity $651.5K$0

Cash flow

Fiscal year FY2025FY2024
Operating cash flow $9.4M—
Investing cash flow -$9.9M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-033988.

Plot the figures US dollars

  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2.5M 5M 7.5M 10M Net income, FY2025: 9.2M FY2024 FY2025
Fiscal year FY2024FY2025
Revenue — —
Gross profit — —
Net income — $9.2M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed Form 10-K
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement signed Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Officer or director change Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 6770

TickerCompanyMarket capP/ERevenue growth
DMII Drugs Made In America Acquisition II Corp. $649.1M — —
IACO Idea Acquisition Corp. $437.9M — —
KRAQ KRAKacquisition Corp $430.8M — —
TACO Berto Acquisition Corp. $393.2M 36.1x —
ATII Archimedes Tech SPAC Partners II Co. $290.3M — —
FGII FG Imperii Acquisition Corp. $290.3M — —
SOUL Soulpower Acquisition Corp. $269.3M — —
DMAA Drugs Made In America Acquisition Corp. $264.0M — —